ReviewThe Journal of pharmacology and experimental therapeutics2019
Oral Drug Delivery Technologies-A Decade of Developments.
Review in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Next-generation composite vesicular systems: an in-depth review of proniosomes in advanced drug delivery.Drug delivery · 2026Review
- Navigating a thorny path: oral nanomedicines for the precision management of radiation-induced intestinal injury.Journal of nanobiotechnology · 2026Review
- Anthocyanin-Rich Pigment Supplements in the Australian Online Market: Sources, Labelling Practices, and Bioactivity Claims.Foods (Basel, Switzerland) · 2026Article
- Breaking the Barrier of Brain Disease Therapeutics: Advocating Targeted Drug Delivery for Improved Neuro-Resident Interventions.AAPS PharmSciTech · 2026Review
- pH-Responsive Nanogels from Bioinspired Comb-like Polymers with Hydrophobic Grafts for Effective Oral Delivery.Gels (Basel, Switzerland) · 2025Article
- Review
- A Comprehensive Review of Challenges in Oral Drug Delivery Systems and Recent Advancements in Innovative Design Strategies.Current pharmaceutical design · 2025Review
- Continuous Oral Administration of the Superantigen Staphylococcal Enterotoxin C2 Activates Intestinal Immunity and Modulates the Gut Microbiota in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The Design Features, Quality by Design Approach, Characterization, Therapeutic Applications, and Clinical Considerations of Transdermal Drug Delivery Systems-A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Suspected poor-quality medicines in Kenya: a retrospective descriptive study of medicine quality-related complaints reports in Kenya's pharmacovigilance database.BMC public health · 2024Article
- Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson's Disease Treatment by Intranasal Administration.Pharmaceutics · 2024Article
- [Evolution of insulin therapy: past, present, future].Problemy endokrinologii · 2024Review
- Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.Drug delivery · 2023Article
- Novel drug delivery strategies for antidepressant active ingredients from natural medicinal plants: the state of the art.Journal of nanobiotechnology · 2023Review
- Polymeric Microarray Patches for Enhanced Transdermal Delivery of the Poorly Soluble Drug Olanzapine.ACS applied materials & interfaces · 2023Article
- Cleanroom-Free Fabrication of Microneedles for Multimodal Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2023Article
- Article
- Beneath the Skin: A Review of Current Trends and Future Prospects of Transdermal Drug Delivery Systems.Pharmaceutics · 2022Review
- Foundations of gastrointestinal-based drug delivery and future developments.Nature reviews. Gastroenterology & hepatology · 2022Review
- Novel Nanoparticles Based onPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Advanced drug delivery technologies, in general, enable drug reformulation and administration routes, together contributing to life-cycle management and allowing the innovator to maintain the product monopoly. Over the years, there has been a steady shift from mere life-cycle management to drug repurposing-applying delivery technologies to tackle solubility and permeability issues in early stages or safety and efficacy issues in the late stages of drug discovery processes. While the drug and the disease in question primarily drive the choice of route of administration, the oral route, for its compliance and safety attributes, is the most preferred route, particularly when it comes to chronic conditions, including pain, which is not considered a disease but a symptom of a primary cause. Therefore, the attempt of this review is to take a stock of the advances in oral delivery technologies that are applicable for injectable to oral transformation, improve risk-benefit profiles of existing orals, and apply them in the early discovery program to minimize the drug attrition rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.